日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The continuing importance of the IARC’s international remit in cancer research

国际癌症研究机构在癌症研究中持续发挥着重要的国际作用

Wang, Xiao; Rothen, John; Huang, Sida; Long, Jessica B; Soulos, Pamela R; Goldberg, Sarah B; Mamtani, Ronac; Presley, Carolyn J; Kunst, Natalia; Ma, Shuangge; Wang, Shi-Yi; Gross, Cary P; Dinan, Michaela A; McCormack, Valerie; Simba, Hannah; Abnet, Christian C; Buckle, Goeffrey; Middleton, Daniel R S; Menya, Diana; Muchengeti, Mazvita; Kantelhardt, Eva J; Addissie, Adamu; Mmbaga, Blandina T; Lemmens, Valery; Sheils, Orla; Boucheron, Pauline; Kim, Joanne; Schüz, Joachim

Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer

降低剂量恩福妥单抗治疗、治疗连续性和尿路上皮癌患者的生存率

Chow, Ryan D; Sedhom, Ramy; Mamtani, Ronac

Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes

电子病历中目标试验模拟的生存结局指标缺失

Shen, Jenny; Linn, Kristin A; Clark, Amy S; Mamtani, Ronac; Hubbard, Rebecca A

Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations

利用基于机器学习的试验模拟评估肿瘤试验结果对真实世界患者的适用性

Orcutt, Xavier; Chen, Kan; Mamtani, Ronac; Long, Qi; Parikh, Ravi B

Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer

右侧 RAS/RAF 野生型结直肠癌的二线治疗策略

Swami, Nishwant; Hwang, Wei-Ting; Mamtani, Ronac; O'Hara, Mark H; Chapin, William J

Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates

免疫检查点抑制剂和抗体药物偶联物治疗前后尿路上皮癌的生存趋势

Lian, Yi; Voruganti, Teja; Lu, Jenny; Long, Qi; Mamtani, Ronac

Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2

利用真实世界数据模拟随机对照试验的注意事项:从 MONALEESA-2 模拟中汲取的经验教训

Kong, Amanda M; Andrean, Dionna; Khan, Saarah; Choi, Julia; Mamtani, Ronac; Parikh, Ravi; Jaksa, Ashley; Campbell, Ulka

Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011-2023: a cross-sectional analysis

2011-2023年美国食品药品监督管理局上市后要求的具体性及其与肿瘤加速审批及时提交申请和监管决策的关联性:一项横断面分析

Kurian, Martin; Ferrell, William J; Ulloa Perez, Ernesto; Hubbard, Rebecca; Joffe, Steven; Mamtani, Ronac; Parikh, Ravi B; Lynch, Holly Fernandez

A Text Message Intervention to Minimize the Time Burden of Cancer Care

利用短信干预减轻癌症治疗的时间负担

Bange, Erin M; Coughlin, Kerry Q; Li, Wenrui; Brown, Timothy J; Ragusano, Daniel; Balar, Eesha; Arasappan, Dhivya; Nnaji, Michelle; Kim, Elliot; Alban, Corey; Uppuluri, Sindhuja; Moriarty, Elizabeth; Bange, Tara; Zinck, Lindsey; Smith, David; Josephs, Michael; Harrigan, James J; Cohen, Roger B; Zubka, Danielle; Rosin, Roy; Balachandran, Mohan; Long, Qi; Bilger, Andrea; Schuchter, Lynn M; Mamtani, Mira; Shulman, Lawrence N; Guerra, Carmen E; Mamtani, Ronac

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

肿瘤突变负荷和PD-L1与帕博利珠单抗联合或不联合化疗治疗晚期尿路上皮癌疗效的相关性

Fléchon, Aude; Morales-Barrera, Rafael; Powles, Thomas; Alva, Ajjai; Özgüroğlu, Mustafa; Csöszi, Tibor; Loriot, Yohann; Rodriguez-Vida, Alejo; Géczi, Lajos; Cheng, Susanna Y; Fradet, Yves; Oudard, Stéphane; Vulsteke, Christof; Gunduz, Seyda; Mamtani, Ronac; Yu, Evan Y; Montesa Pino, Alvaro; Anido, Urbano; Sendur, Mehmet A N; Gravis, Gwenaelle; Révész, János; Kostorov, Vladimir; Huillard, Olivier; Ma, Junshui; Rajasagi, Mohini; Vajdi, Amir; Lunceford, Jared; Cristescu, Razvan; Imai, Kentaro; Homet Moreno, Blanca; Matsubara, Nobuaki